文献速递心境障碍儿童青少年精神会诊联络精神医学

妊娠期抑郁症与SSRI治疗:优先关注母亲心理健康

Depression and SSRI Treatment During Pregnancy-Prioritizing Maternal Mental Health.
PubMed 文献 · JAMA Psychiatry · 2026-01-01

本文综述妊娠期重度抑郁症(MDD)的患病率及SSRI治疗现状,指出围产期精神病学疾病是孕产妇发病和死亡的主要原因之一。观察性研究因适应证混杂而难以评估SSRI安全性,但累积证据提示SSRI严重不良结局风险很小或没有风险。领域重点已转向优先治疗MDD以优化母亲健康。

要点

  • 美国5%至6%的孕妇使用SSRI,主要用于患病率约12%的重度抑郁症。
  • 观察性研究因适应证混杂难以评估SSRI安全性,但累积证据提示严重不良结局风险很小或没有风险。
  • 领域重点已转向优先治疗MDD以优化母亲健康,并需协调多层面临床照护与研究。

核心结论

  • 妊娠期MDD必须治疗以改善母亲、婴儿、家庭和社区结局,SSRI是围产期精神卫生保健的重要组成部分。
  • 一旦将药物影响与MDD及其后遗症区分开,累积证据提示SSRI严重不良结局风险很小或没有风险。
  • 领域重点已转向优先治疗MDD以优化母亲健康。

研究设计与样本

  • 本文为JAMA Psychiatry发表的综述/观点类文章,基于文献汇总而非原始研究。

主要发现

  • 美国5%至6%的孕妇使用SSRI,主要用于患病率约12%的重度抑郁症。
  • 围产期特有因素与MDD相关的额外病理生理变化有关,母亲压力和精神病学疾病对胎儿和婴儿结局有不良影响。
  • 定义妊娠期SSRI治疗获益的研究少于定义风险的研究,但多项研究描述中重度MDD女性停药后的不良效应。
  • 观察性研究因适应证和相关因素的潜在混杂,评估妊娠期SSRI安全性具有挑战性。

关键数值与推荐

  • 美国5%至6%的孕妇使用SSRI,主要用于患病率约12%的重度抑郁症。

临床怎么用

  • 结构化决策过程有助于提供关于未治疗或治疗不足疾病的潜在母胎风险、治疗获益及SSRI暴露相关风险的平衡信息。
  • 扩大照护可及性,尤其是在产科、儿童保健和精神科照护荒漠地区,是公共卫生当务之急。
  • 临床需协调多层面照护,并兼顾两代人的健康需求。

局限性

  • 定义妊娠期SSRI治疗获益的研究少于定义风险的研究。
  • 观察性研究存在适应证和相关因素的潜在混杂,使安全性评估具有挑战性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: In the US, 5% to 6% of pregnant patients are treated with selective serotonin reuptake inhibitors (SSRI), primarily for major depressive disorder (MDD), which has a prevalence of about 12%. Psychiatric conditions are a leading cause of maternal morbidity and mortality. MDD is a common disorder that must be treated during pregnancy to improve outcomes for the mother, infant, family, and community. OBSERVATIONS: MDD is a complex, multifactorial brain disease arising from genetic, environmental, and epigenetic factors. Factors unique to the perinatal period are associated with additional pathophysiologic changes specific to MDD. Maternal stress and psychiatric illnesses adversely affect fetal and infant outcomes. SSRI are an essential component of perinatal mental health care. Studies that define the benefits of SSRI treatment in pregnancy are fewer than those defining risks; however, several describe adverse effects with drug discontinuation in women with moderate to severe MDD. Evaluating the safety of SSRI treatment during pregnancy has been challenging due to the potential for confounding in observational studies by the underlying indication and associated factors. Once the impact of the drug is disentangled from that of MDD and its sequelae, accumulated evidence suggests that SSRI carry little or no risk for serious adverse outcomes. The thrust of the field has shifted to prioritize treatment of MDD to optimize maternal health. CONCLUSIONS AND RELEVANCE: Meaningful advances in the treatment of perinatal MDD require coordinated attention to multiple aspects of clinical care delivery and research, informed by a perspective accounting for the health needs of 2 generations. Expanding access to care-particularly in maternity, child health, and psychiatric care deserts-is a public health imperative. A structured decision-making process facilitates the provision of balanced information on the potential maternal and fetal risks of untreated or undertreated illness, the benefits of treatment, and the risks associated with SSRI exposure.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Wisner KL, Oberlander TF, Osborne LM, et al. Depression and SSRI Treatment During Pregnancy-Prioritizing Maternal Mental Health. JAMA Psychiatry. 2026. PMID: 42584886. doi:10.1001/jamapsychiatry.2026.2405

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。